Status:
COMPLETED
Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Brief Summary
To evaluate the QOL (subjective effectiveness) in patients with schizophrenia, treated with atypical antipsychotics.
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia
- Treatment with one atypical antipsychotic\* (for a first/new episode or a switch of therapy) for at least 2 weeks and maximum 8 weeks prior to the first study visit.
- Patient takes an AAP according to local SPC and current medical practice
- The patient must be able to understand and comply with the study requirements as judged by the investigator, e.g. patient must be able to read and write
Exclusion
- Treatment with an additional AAP or AP to the initial prescribed AAP within the 2-8 weeks before the patient is included in the study
- Since the use of clozapine is limited, due to, among other things, the risk for agranulocytosis, patients on treatment with this '2nd line'AAP are excluded.
- Previous enrolment or treatment in the present NIS
- Known allergy to the prescribed AAP or any of its substances
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT00689325
Start Date
April 1 2008
End Date
January 1 2010
Last Update
October 27 2010
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Alphen, Netherlands
2
Research Site
Amersfoort, Netherlands
3
Research Site
Amstelveen, Netherlands
4
Research Site
Amsterdam, Netherlands